Cargando…

Real-world data assessment of safety of home-based and hospital/outpatient-based laronidase enzyme replacement therapy for mucopolysaccharidosis I

Detalles Bibliográficos
Autores principales:	Wilson, Amanda, Colzani, Raffaella M., Flores, Ana Lorena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178685/ https://www.ncbi.nlm.nih.gov/pubmed/34136352 http://dx.doi.org/10.1016/j.ymgmr.2021.100736

Ejemplares similares

Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease
por: Hsu, Yu-Hone, et al.
Publicado: (2017)

Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I
por: Giugliani, Roberto, et al.
Publicado: (2017)

The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis()
por: Dualibi, Ana Paula Fiuza Funicello, et al.
Publicado: (2015)

Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS)
por: Spataro, Federico, et al.
Publicado: (2022)

Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis
por: Dornelles, Alícia Dorneles, et al.
Publicado: (2017)

Data from subjects receiving intrathecal laronidase for cervical spinal stenosis due to mucopolysaccharidosis type I
por: Dickson, P.I., et al.
Publicado: (2015)

Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series
por: Horovitz, Dafne Dain Gandelman, et al.
Publicado: (2016)

Multicenter, non-interventional, double cohort study to assess the safety of alglucosidase alfa and laronidase in real-world home infusion setting
por: Toscano, Antonio, et al.
Publicado: (2022)

Post-transplant laronidase augmentation for children with Hurler syndrome: biochemical outcomes
por: Lund, Troy C., et al.
Publicado: (2019)

Clinical trial of laronidase in Hurler syndrome after hematopoietic cell transplantation
por: Polgreen, Lynda E., et al.
Publicado: (2019)

Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II
por: Schulze-Frenking, G., et al.
Publicado: (2010)

Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA
por: Lin, Hsiang-Yu, et al.
Publicado: (2018)

Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I
por: Nestrasil, Igor, et al.
Publicado: (2017)

Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I
por: Ghosh, Arunabha, et al.
Publicado: (2019)

Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II
por: Seo, Joo-Hyun, et al.
Publicado: (2021)

Erratum: Clinical, radiologic, and genetic features of Korean patients with Mucopolysaccharidosis IVA
por: Lee, Na Hee, et al.
Publicado: (2013)

Identifying “Real” Patients in the Real World
por: Callahan, Sean J.
Publicado: (2020)

Clinical and event-based outcomes of patients with mucopolysaccharidosis VI receiving enzyme replacement therapy in Turkey: a case series
por: İnci, Aslı, et al.
Publicado: (2021)

Safety outcomes and patients’ preferences for home-based intravenous enzyme replacement therapy (ERT) in pompe disease and mucopolysaccharidosis type I (MPS I) disorder: COVID-19 and beyond
por: Toscano, Antonio, et al.
Publicado: (2023)

Real world and hyper reality
por: Gautret, Philippe, et al.
Publicado: (2021)

Reply to Callahan: Identifying “Real” Patients in the Real World
por: Dempsey, Timothy M.
Publicado: (2020)

Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme(®)) therapy
por: Braunlin, E., et al.
Publicado: (2012)

Effects of Enzyme Replacement Therapy Started Late in a Murine Model of Mucopolysaccharidosis Type I
por: Pasqualim, Gabriela, et al.
Publicado: (2015)

Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study
por: Ficicioglu, Can, et al.
Publicado: (2020)

Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries
por: Magner, Martin, et al.
Publicado: (2022)

Dose-dependent effects of enzyme replacement therapy on skeletal disease progression in mucopolysaccharidosis VII dogs
por: Gawri, Rahul, et al.
Publicado: (2022)

Not All Home-based Exercise Programs Are Home-based Pulmonary Rehabilitation Programs
por: Moy, Marilyn L.
Publicado: (2019)

A boy with mucopolysaccharidosis type II accompanied with a novel variation in heparan-N-sulfatase
por: Li, Yu-Jue, et al.
Publicado: (2019)

CASE SERIES OF PATIENTS UNDER BIWEEKLY TREATMENT WITH LARONIDASE: A REPORT OF A SINGLE CENTER EXPERIENCE
por: Kyosen, Sandra Obikawa, et al.
Publicado: (2019)

Anti-TNF-Alpha Therapy Enhances the Effects of Enzyme Replacement Therapy in Rats with Mucopolysaccharidosis Type VI
por: Eliyahu, Efrat, et al.
Publicado: (2011)

Mucopolysaccharidosis: Cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI
por: Brands, Marion M. M. G., et al.
Publicado: (2012)

Impact of Enzyme Replacement Therapy on Linear Growth in Korean Patients with Mucopolysaccharidosis Type II (Hunter Syndrome)
por: Cho, Sung Yoon, et al.
Publicado: (2014)

Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network
por: Dornelles, Alícia Dorneles, et al.
Publicado: (2014)

Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series
por: Lin, Hsiang-Yu, et al.
Publicado: (2016)

A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I
por: Le, Steven Q., et al.
Publicado: (2017)

Recovery of Vision following Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II, Hunter Syndrome
por: Yamanishi, Ryutaro, et al.
Publicado: (2019)

Enzyme replacement therapy interruption in mucopolysaccharidosis type IVA patients and its impact in different clinical outcomes
por: Politei, Juan, et al.
Publicado: (2021)

Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data
por: Giugliani, Roberto, et al.
Publicado: (2021)

Clinical characteristics and effects of enzyme replacement therapy with elosulfase alfa in Korean patients with mucopolysaccharidosis type IVA
por: Lee, Seung Hoon, et al.
Publicado: (2022)

Reply to Moy: Not All Home-based Exercise Programs Are Home-based Pulmonary Rehabilitation Programs
por: Bhatt, Surya P., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_o4l8hhj7fch819n0cbqbjia4ot